{"publication_id":"bd4ddec9-e10e-445f-bf0b-a5399dfae223","screening":{"identified":41,"screened":41,"excluded":0,"included":41,"included_or_retained":41,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"41 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Across the corpus, observational and cohort studies overwhelmingly dominate the literature; mechanistic preclinical work exists but direct randomized clinical trial evidence for interventions that modulate immune aging in humans remains sparse.","The current evidence base for immune aging is therefore context-dependent and predominantly observational, with null-effect findings common across outcome classes; mechanistic plausibility is consistent with but the boundary conditions, magnitude of modifiable risk, and hard clinical endpoints remain insufficiently defined to support broad therapeutic translation.","A primary limitation is the absence of large, prospective, randomized controlled trials designed to test immune aging interventions against hard clinical endpoints. The curated corpus is overwhelmingly composed of observational cohort studies and exploratory biomarker analyses, such as Nakanjako 2024 and Davies 2025, which report associations between immune markers and age or disease state. There are no trials in this corpus that randomize an intervention to slow immune aging and follow participants for outcomes like all-cause mortality, incident frailty, or infection rates over several years. Consequently, the synthesis can describe correlations and mechanistic plausibility but cannot provide causal evidence that modifying these immune parameters translates into improved long-term health or longevity. This absence represents a critical gap, as the clinical relevance of any immune age biomarker remains uncertain without evidence from an intervention trial demonstrating a causal benefit.","The evidence base is also limited by its heavy reliance on findings from single studies for specific outcomes, which precludes internal replication within the corpus. For instance, the association between social relationships and immune aging in early midlife is reported by only one source, Rob 2025. Similarly, the connection between immune age and decreased antibody response to vaccination is based solely on Davies 2025. While these studies report statistically significant associations, the reliance on single studies for these particular claims means their robustness and generalizability cannot be corroborated by other independent analyses in this synthesis. This single-trial risk introduces uncertainty, as findings from one study may be influenced by unique cohort characteristics, analytical choices, or chance, and require validation in distinct populations.","Finally, the corpus primarily characterizes immune aging through cellular and molecular profiling endpoints, with a notable scarcity of evidence linking these markers to clinically relevant functional outcomes. Studies such as Fang 2025 and Brode 2023 provide detailed assessments of TCR repertoire diversity and immune cell subsets, which are mechanistic indicators. However, there is limited direct evidence within the corpus connecting these specific biomarker profiles to tangible patient-centered outcomes like physical function, disability, or infection susceptibility. While Noppert 2023 links a marker of immune aging (CD8+:CD4+ ratio) to disability prevalence, this represents a bridge between a surrogate marker and a clinical outcome, a link that is not consistently established across the evidence base for all proposed biomarkers of immune age. The synthesis is therefore largely built upon a foundation of surrogate endpoints (Ioannidis 2005).","For immune age, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immune age as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 41 curated reference papers, the evidence base for Immune age shows a context-dependent profile. Null findings dominate: immune inflammation, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Immune age anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}